DDrare: Database of Drug Development for Rare Diseases

Searched query = "Osler disease", "Hereditary hemorrhagic telangiectasia", "Osler-Weber-Rendu disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = AVASTIN; AVASTIN 25 mg/ml - Konzentrat zur Herstellung einer Infusionsloesung; Acetate; Avastin; BEVACIZUMAB; Bevacizumab; Bevacuzimab spray; Blood samples; Chloride; Dicynone; Doxycycline; Doxycycline Hyclate; EMEA/H/C/000712; ETAMSYLATE; Estriol; Etamsylate; Ferrous sulphate 200mg oral tablet; Floseal; Gold; Itraconazole; Mupirocin; NINTEDANIB; NaCl; Nintedanib; Nintédanib; OCTREOTIDE; OCTREOTIDE ACETATE; OFEV; Octreotide; Octreotide LAR; Other: Epistaxis charts; Other: Packing; Other: Standard Treatment; Other: Standard care; PHYSIOLOGISCHE Kochsalzloesung Fresenius - Infusionsloesung; Pazopanib; Pegylated Interferon Alpha2b; Pomalidomide; Pomalidomide Oral Product; Propranolol; Propranolol treatment; RVG 18236; Ranibizumab; SODIUM CHLORIDE; SUB16402MIG; Sandostatin LAR; Sandostatin LAR 20 mg; Sclerotherapy; Sodium chloride; Soy protein isolate; Sporanox; Sterile saline; Submucosal Bevacizumab; THALIDOMIDE; THALIDOMIDE CELGENE*28CPS 50MG; TIMOLOL MALEATE; Tacrolimus; Tacrolimus (Advagraf); Tacrolimus capsule (low-dose); Tamoxifen; Thalidomide; Timolol; Timolol Alcon 0.5% collyre; Timolol Gel; Timolol nasal spray; Topical timolol maleate; Tranexamic Acid; Tranexamic acid; Vit D

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03850730 (ClinicalTrials.gov)	September 2019	12/2/2019	Pazopanib for the Treatment of Epistaxis in Hereditary Hemorrhagic Telangiectasia	An Open-label, Non-randomized Study of the Efficacy of Pazopanib for the Treatment of Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)	Hereditary Hemorrhagic Telangiectasia;Epistaxis	Drug: Pazopanib	Cure HHT	University of North Carolina	Not yet recruiting	18 Years	75 Years	All	30	Phase 1;Phase 2	NULL
2	NCT03850964 (ClinicalTrials.gov)	September 2019	12/2/2019	Pazopanib Effects on Bleeding in Hereditary Hemorrhagic Telangiectasia	Randomized Double Blind Study to Evaluate the Effect of Low Dose Pazopanib on Bleeding Due to Hereditary Hemorrhagic Telangiectasia	Hereditary Hemorrhagic Telangiectasia;Epistaxis Nosebleed;Anemia	Drug: Pazopanib;Drug: Placebo oral capsule	Cure HHT	NULL	Not yet recruiting	18 Years	75 Years	All	45	Phase 2;Phase 3	NULL

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT03850730
(ClinicalTrials.gov)

September 2019

12/2/2019

Pazopanib for the Treatment of Epistaxis in Hereditary Hemorrhagic Telangiectasia

An Open-label, Non-randomized Study of the Efficacy of Pazopanib for the Treatment of Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)

Hereditary Hemorrhagic Telangiectasia;Epistaxis

Drug: Pazopanib

Cure HHT

University of North Carolina

Not yet recruiting

18 Years

75 Years

All

Phase 1;Phase 2

NULL

NCT03850964
(ClinicalTrials.gov)

September 2019

12/2/2019

Pazopanib Effects on Bleeding in Hereditary Hemorrhagic Telangiectasia

Randomized Double Blind Study to Evaluate the Effect of Low Dose Pazopanib on Bleeding Due to Hereditary Hemorrhagic Telangiectasia

Hereditary Hemorrhagic Telangiectasia;Epistaxis Nosebleed;Anemia

Drug: Pazopanib;Drug: Placebo oral capsule

Cure HHT

NULL

Not yet recruiting

18 Years

75 Years

All

Phase 2;Phase 3

NULL